355 related articles for article (PubMed ID: 29656849)
41. The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study.
Yang CH; Chen KJ; Tsai JJ; Lin YH; Cheng SH; Wang KF; Chiou HY
BMC Infect Dis; 2014 Jun; 14():304. PubMed ID: 24897928
[TBL] [Abstract][Full Text] [Related]
42. Impact of HAART therapy on co-infection of tuberculosis and HIV cases for 9 years in Taiwan.
Tseng SH; Jiang DD; Hoi HS; Yang SL; Hwang KP
Am J Trop Med Hyg; 2009 Apr; 80(4):675-7. PubMed ID: 19346398
[TBL] [Abstract][Full Text] [Related]
43. Simultaneous HAART improves survival in children coinfected with HIV and TB.
Pensi T; Hemal A; Banerjee T
Trop Med Int Health; 2012 Jan; 17(1):52-8. PubMed ID: 21967134
[TBL] [Abstract][Full Text] [Related]
44. Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda.
Baalwa J; Mayanja-Kizza H; Kamya MR; John L; Kambugu A; Colebunders R
Afr Health Sci; 2008 Sep; 8(3):190-5. PubMed ID: 19357749
[TBL] [Abstract][Full Text] [Related]
45. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy.
Dheda K; Lampe FC; Johnson MA; Lipman MC
J Infect Dis; 2004 Nov; 190(9):1670-6. PubMed ID: 15478074
[TBL] [Abstract][Full Text] [Related]
46. Inflammation and micronutrient biomarkers predict clinical HIV treatment failure and incident active TB in HIV-infected adults: a case-control study.
Shivakoti R; Gupte N; Tripathy S; Poongulali S; Kanyama C; Berendes S; Cardoso SW; Santos BR; La Rosa A; Mwelase N; Pillay S; Samaneka W; Riviere C; Sugandhavesa P; Bollinger RC; Balagopal A; Semba RD; Christian P; Campbell TB; Gupta A;
BMC Med; 2018 Sep; 16(1):161. PubMed ID: 30244671
[TBL] [Abstract][Full Text] [Related]
47. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.
Ylitalo N; Brogly S; Hughes MD; Nachman S; Dankner W; Van Dyke R; Seage GR;
Arch Pediatr Adolesc Med; 2006 Aug; 160(8):778-87. PubMed ID: 16894075
[TBL] [Abstract][Full Text] [Related]
48. Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: a retrospective cohort study.
Ahmed A; Mekonnen D; Shiferaw AM; Belayneh F; Yenit MK
BMJ Open; 2018 Feb; 8(2):e016961. PubMed ID: 29437750
[TBL] [Abstract][Full Text] [Related]
49. Safety and effectiveness of HAART in tuberculosis-HIV co-infected patients in Brazil.
dos Santos AP; Pacheco AG; Staviack A; Golub JE; Chaisson RE; Rolla VC; Kritski AL; Passos SR; de Queiroz Mello FC
Int J Tuberc Lung Dis; 2013 Feb; 17(2):192-7. PubMed ID: 23317954
[TBL] [Abstract][Full Text] [Related]
50. Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy.
Karo B; Krause G; Castell S; Kollan C; Hamouda O; Haas W;
BMC Infect Dis; 2017 Jul; 17(1):517. PubMed ID: 28743248
[TBL] [Abstract][Full Text] [Related]
51. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus.
López-Gatell H; Cole SR; Hessol NA; French AL; Greenblatt RM; Landesman S; Preston-Martin S; Anastos K
Am J Epidemiol; 2007 May; 165(10):1134-42. PubMed ID: 17339383
[TBL] [Abstract][Full Text] [Related]
52. Tuberculosis along the continuum of HIV care in a cohort of adolescents living with HIV in Ethiopia.
Jerene D; Abebe W; Taye K; Suarez PG; Feleke Y; Hallström I; Ruff AJ
Int J Tuberc Lung Dis; 2017 Jan; 21(1):32-37. PubMed ID: 28157462
[TBL] [Abstract][Full Text] [Related]
53. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
[TBL] [Abstract][Full Text] [Related]
54. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study.
Podlekareva DN; Efsen AM; Schultze A; Post FA; Skrahina AM; Panteleev A; Furrer H; Miller RF; Losso MH; Toibaro J; Miro JM; Vassilenko A; Girardi E; Bruyand M; Obel N; Lundgren JD; Mocroft A; Kirk O;
Lancet HIV; 2016 Mar; 3(3):e120-31. PubMed ID: 26939735
[TBL] [Abstract][Full Text] [Related]
55. Development of tuberculosis in human immunodeficiency virus infected patients receiving antiretroviral therapy.
Martín-Echevarria E; Serrano-Villar S; Sainz T; Moreno A; Casado JL; Dronda F; Elías MJ; Navas E; Zapata MR; Moreno S
Int J Tuberc Lung Dis; 2014 Sep; 18(9):1080-4. PubMed ID: 25189556
[TBL] [Abstract][Full Text] [Related]
56. Post-HAART tuberculosis in adults and adolescents with HIV in India: incidence, clinical and immunological profile.
Rajasekaran S; Raja K; Jeyaseelan L; Vijilat S; Priya K; Mohan K; Parvez A; Mahilmaran A; Chandrasekar C
Indian J Tuberc; 2009 Apr; 56(2):69-76. PubMed ID: 19810588
[TBL] [Abstract][Full Text] [Related]
57. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.
Dean GL; Edwards SG; Ives NJ; Matthews G; Fox EF; Navaratne L; Fisher M; Taylor GP; Miller R; Taylor CB; de Ruiter A; Pozniak AL
AIDS; 2002 Jan; 16(1):75-83. PubMed ID: 11741165
[TBL] [Abstract][Full Text] [Related]
58. Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy?
Breen RA; Smith CJ; Cropley I; Johnson MA; Lipman MC
AIDS; 2005 Jul; 19(11):1201-6. PubMed ID: 15990574
[TBL] [Abstract][Full Text] [Related]
59. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy.
Shelburne SA; Visnegarwala F; Darcourt J; Graviss EA; Giordano TP; White AC; Hamill RJ
AIDS; 2005 Mar; 19(4):399-406. PubMed ID: 15750393
[TBL] [Abstract][Full Text] [Related]
60. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD.
Kirk O; Gatell JM; Mocroft A; Pedersen C; Proenca R; Brettle RP; Barton SE; Sudre P; Phillips AN
Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 1):865-72. PubMed ID: 10988097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
